Lakewood-Amedex Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
LABT
- Share Price
-
$0.27
- (As of Friday Closing)
Lakewood-Amedex General Information
Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Contact Information
Website
www.lakewoodamedex.comCorporate Office
- 8031 Cooper Creek Boulevard
- Suite 103
- University Park, FL 34201
- United States
Corporate Office
- 8031 Cooper Creek Boulevard
- Suite 103
- University Park, FL 34201
- United States
Lakewood-Amedex Stock Performance
As of 13-Nov-2026, Lakewood-Amedex’s stock price is $0.27. Its current market cap is $669K with 2.37M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.27 | $0.36 | $0.17 - $98.20 | $669K | 2.37M | 14.9M | -$8.83 |
Lakewood-Amedex Financials Summary
As of 30-Jun-2026, Lakewood-Amedex has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,245 | |||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (7,147) | (3,652) | (4,874) | (8,511) |
| Net Income | (7,347) | (3,848) | (4,855) | (8,282) |
| Total Assets | 4,960 | 482 | 1,071 | 6,894 |
| Total Debt | 102 | 1,660 | 273 | 579 |
Lakewood-Amedex Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lakewood-Amedex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Lakewood-Amedex Comparisons
Industry
Financing
Details
Lakewood-Amedex Competitors (2)
One of Lakewood-Amedex’s 2 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| BioCryst Pharmaceuticals | Corporation | Durham, NC |
Lakewood-Amedex Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lakewood-Amedex Patents
Lakewood-Amedex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025224691-A1 | Crystalline forms of nu-3 and uses thereof | Pending | 22-Feb-2024 | ||
| WO-2025179296-A1 | Crystalline forms of nu-3 and uses thereof | Pending | 22-Feb-2024 | ||
| EP-4704829-A2 | Substituted bicyclic heterocycle compounds, compositions, and uses thereof | Pending | 26-Apr-2023 | ||
| US-20260294949-A1 | Substituted bicyclic heterocycle compounds, compositions, and uses thereof | Pending | 26-Apr-2023 | ||
| WO-2024226872-A2 | Substituted bicyclic heterocycle compounds, compositions, and uses thereof | Inactive | 26-Apr-2023 | C07F9/65616 |
Lakewood-Amedex Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lakewood-Amedex ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Lakewood-Amedex FAQs
-
When was Lakewood-Amedex founded?
Lakewood-Amedex was founded in 2006.
-
Where is Lakewood-Amedex headquartered?
Lakewood-Amedex is headquartered in University Park, FL.
-
What is the size of Lakewood-Amedex?
Lakewood-Amedex has 5 total employees.
-
What industry is Lakewood-Amedex in?
Lakewood-Amedex’s primary industry is Drug Discovery.
-
Is Lakewood-Amedex a private or public company?
Lakewood-Amedex is a Public company.
-
What is Lakewood-Amedex’s stock symbol?
The ticker symbol for Lakewood-Amedex is LABT.
-
What is the current stock price of Lakewood-Amedex?
As of 13-Nov-2026 the stock price of Lakewood-Amedex is $0.27.
-
What is the current market cap of Lakewood-Amedex?
The current market capitalization of Lakewood-Amedex is $669K.
-
Who are Lakewood-Amedex’s competitors?
Spero Therapeutics and BioCryst Pharmaceuticals are competitors of Lakewood-Amedex.
-
What is Lakewood-Amedex’s annual earnings per share (EPS)?
Lakewood-Amedex’s EPS for 12 months was -$8.83.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
